Xebra Brands' cannabis cultivation in the Netherlands is in the flowering stage, as Xebra readies to harvest and submit samples of its crop to Dutch authorities, by the end of March. Two samples will be delivered, one with high THC ±22%, and one with balanced THC ±6% and CBD± 8%.
As 1 of only 5 companies to be selected by the Dutch government to participate in a medicinal cannabis cultivation pilot trial, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to ~US$80 million (€70.5 million), to co-supply all pharma-grade cannabis to be sold though pharmacies in the Netherlands
The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters."We are extremely pleased with our smooth and successful results to date, as we carefully monitor every growth stage," commented Rodrigo Gallardo, President of Xebra. "Our innovated equipment made it possible for us to automate much of the growing process from germination to flowering, ensuring maximum consistency," further commented Mr. Gallardo.
Cultivation in the Netherlands is conducted in Xebra's indoor facility. "Xebra's specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks."
For more information:
Xebra Brands
www.xebrabrands.com